Posts

FDA Reassesses Rare-Disease Trial Standards and Endpoint Selection

on

GSK to wind down Dresden vaccine factory amid weak flu-vaccine demand

on

Ivonescimab Shows Survival Advantage Over Keytruda in Lung Cancer Trial

on

Cyclic peptides advance toward new drug targets, but manufacturing capacity may determine how fast

on

Allarity Therapeutics Files Registration Statement for Proposed $100 Million SPAC IPO

on

GSK’s Ris-Rez cuts death risk by 54% in relapsed small-cell lung cancer trial

on

Novartis board faces investor scrutiny after M&A misfires and R&D setbacks

on

Major Novartis shareholder calls for board shake-up after trial setbacks

on

Major Novartis shareholder calls for board shake-up after trial setbacks

on

Novartis’s Triple Clinical Setback Hits Shares and Weighs on Pharma Peers

on

FDA delays decision on Exelixis colorectal-cancer drug to March 2027

on

Lonza and CordenPharma expand US and injectable manufacturing capacity

on

Yarrow raises $150M

on